The US Food and Drug Administration recently approved KOVANAZE, the first nasal-administered dental anesthetic.
Here are five key notes:
1. KOVANAZE is the first product developed by the Fort Collins, Colo.-based company St. Renatus.
2. Traditionally, the dental industry has used needle injected anesthetic. However, KOVANAZE is administered through a nasal spray, without the use of a needle.
3. KOVANAZE contains tetracaineHCl (an ester local anesthetic) and oxymetazolineHCl (a vasoconstrictor).
4. The nasal spray is a topical, tooth nerve anesthetic, developed for dental procedures involving the upper teeth.
5. St. Renatus specifies that the anesthetic is meant for restoratives procedures on Teeth 4 through 13 and A through J in adults and children who weigh more than 40 kilograms.